NCT03215030 · OUTCOME
Part 3: Number of Participants at Baseline and at Worst Post-baseline Status as Categorized by Eastern Cooperative Oncology Group (ECOG) Performance Status
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma · Source last updated 2026-01-29
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Up to 20.5 months in Part 3
What was measured
ECOG performance status was measured at baseline and over time. ECOG performance status was measured on a 6 point scale: Grade 0: Normal activity, Grade 1: Symptoms but ambulatory, Grade 2: In bed \<50% of the time, Grade 3: In bed \>50% of the time, Grade 4: 100% bedridden, Grade 5: Dead. Reported here is the baseline status and the worst post-baseline status measured. A decrease in grade from baseline indicates an improvement. Only categories for which there was at least 1 participant are reported.
Analysis population: The SAS included all enrolled participants who received at least 1 dose, even if incomplete, of TAK-573.
Groups in this outcome
Part 3 (Dose Extension): Modakafusp Alfa 120 mg
Participants received modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
Part 3 (Dose Extension): Modakafusp Alfa 240 mg
Participants received modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 120 mg | 68 |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 240 mg | 63 |
|---|
Reported measurements
Baseline: 0; Worst Post-baseline: 0
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 120 mg | 11 | Not reported | Not reported | Not reported | Not reported |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 240 mg | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
Baseline: 0; Worst Post-baseline: 1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 120 mg | 5 | Not reported | Not reported | Not reported | Not reported |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 240 mg | 12 | Not reported | Not reported | Not reported | Not reported |
|---|
Baseline: 0; Worst Post-baseline: 2
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 120 mg | 2 | Not reported | Not reported | Not reported | Not reported |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 240 mg | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
Baseline: 0; Worst Post-baseline: 3
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 120 mg | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 240 mg | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
Baseline: 1; Worst Post-baseline: 0
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 120 mg | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 240 mg | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Baseline: 1; Worst Post-baseline: 1
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 120 mg | 31 | Not reported | Not reported | Not reported | Not reported |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 240 mg | 25 | Not reported | Not reported | Not reported | Not reported |
|---|
Baseline: 1; Worst Post-baseline: 2
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 120 mg | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 240 mg | 12 | Not reported | Not reported | Not reported | Not reported |
|---|
Baseline: 1; Worst Post-baseline: 3
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 120 mg | 3 | Not reported | Not reported | Not reported | Not reported |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 240 mg | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
Baseline: 1; Worst Post-baseline: 4
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 120 mg | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 240 mg | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Baseline: 2; Worst Post-baseline: 2
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 120 mg | 6 | Not reported | Not reported | Not reported | Not reported |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 240 mg | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
Baseline: 2; Worst Post-baseline: 3
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 120 mg | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 240 mg | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
Baseline: 2; Worst Post-baseline: 4
Values in Participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 120 mg | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
| Part 3 (Dose Extension): Modakafusp Alfa 240 mg | 0 | Not reported | Not reported | Not reported | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 11
- group Id
- OG001
- value
- 6
- title
- Baseline: 0; Worst Post-baseline: 0
- categories
- measurements
- group Id
- OG000
- value
- 5
- group Id
- OG001
- value
- 12
- title
- Baseline: 0; Worst Post-baseline: 1
- categories
- measurements
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 1
- title
- Baseline: 0; Worst Post-baseline: 2
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 1
- title
- Baseline: 0; Worst Post-baseline: 3
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- title
- Baseline: 1; Worst Post-baseline: 0
- categories
- measurements
- group Id
- OG000
- value
- 31
- group Id
- OG001
- value
- 25
- title
- Baseline: 1; Worst Post-baseline: 1
- categories
- measurements
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 12
- title
- Baseline: 1; Worst Post-baseline: 2
- categories
- measurements
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 1
- title
- Baseline: 1; Worst Post-baseline: 3
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- title
- Baseline: 1; Worst Post-baseline: 4
- categories
- measurements
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 4
- title
- Baseline: 2; Worst Post-baseline: 2
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 1
- title
- Baseline: 2; Worst Post-baseline: 3
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- title
- Baseline: 2; Worst Post-baseline: 4
- denoms
- counts
- group Id
- OG000
- value
- 68
- group Id
- OG001
- value
- 63
- units
- Participants
- description
- ECOG performance status was measured at baseline and over time. ECOG performance status was measured on a 6 point scale: Grade 0: Normal activity, Grade 1: Symptoms but ambulatory, Grade 2: In bed \<50% of the time, Grade 3: In bed \>50% of the time, Grade 4: 100% bedridden, Grade 5: Dead. Reported here is the baseline status and the worst post-baseline status measured. A decrease in grade from baseline indicates an improvement. Only categories for which there was at least 1 participant are reported.
- groups
- description
- Participants received modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
- id
- OG000
- title
- Part 3 (Dose Extension): Modakafusp Alfa 120 mg
- description
- Participants received modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
- id
- OG001
- title
- Part 3 (Dose Extension): Modakafusp Alfa 240 mg
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- The SAS included all enrolled participants who received at least 1 dose, even if incomplete, of TAK-573.
- reporting Status
- POSTED
- time Frame
- Up to 20.5 months in Part 3
- title
- Part 3: Number of Participants at Baseline and at Worst Post-baseline Status as Categorized by Eastern Cooperative Oncology Group (ECOG) Performance Status
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle